Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies

2024-9-9

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations

2024-9-9

Optimizing long-term joint health in the treatment of hemophilia

2024-9-8

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

2024-8-20

Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?

2024-8-19

Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer?

2024-8-9

Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review

2024-8-8

DNA damage repair in megakaryopoiesis: molecular and clinical aspects

2024-8-8

Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia

2024-8-7

Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma

2024-8-7

What is the future of digital tools to help manage pain in sickle cell disease patients?

2024-8-6

Exploring health disparities in diagnosing multiple myeloma

2024-8-6

Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management

2024-8-6

Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies

2024-8-6

A comprehensive review on gelatinous transformation of the bone marrow

2024-7-31

Gene therapies on the horizon for sickle cell disease: a clinician’s perspective

2024-7-30

The medication usage pattern and prevalence of polypharmacy among patients with sickle cell disease: a population-based study in southern Iran

2024-7-27

Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide

2024-7-26

Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes

2024-7-23

Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia

2024-7-23

How can we optimize antifungal use and stewardship in the treatment of acute leukemia?

2024-7-22

Anemia and iron overload as prognostic markers of outcomes in β-thalassemia

2024-7-22

Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!

2024-7-22

Ultrasound-guided joint procedures in hemophilia: technique, indications and tips

2024-7-15

Joint health and pain in the changing hemophilia treatment landscape

2024-7-10

Quality of life considerations in myelodysplastic syndrome: not only fatigue

2024-7-6

Can we use biomarkers to identify those at risk of acute pain from sickle cell disease?

2024-7-1

Update on iron supplementation in patients with cancer-related anemia

2024-7-1

The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms

2024-6-28

Optimising salvage therapy for Hodgkin lymphoma: progress and future challenges

2024-6-27

Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women

2024-6-26

Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

2024-6-25

Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors

2024-6-20

Outcome measures in hemophilia: current and future perspectives

2024-6-19

T-cell exhaustion in multiple myeloma

2024-6-19

Reduction of ristocetin-induced platelet aggregation (RIPA) during storage despite plasma renewal: evidence for hemostatic importance of GPIbα shedding

2024-6-18

Correction

2024-6-18

The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease

2024-6-13

Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints

2024-6-10

Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature

2024-6-6

Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma

2024-5-24

Early diagnosis of persons with von Willebrand disease using a machine learning algorithm and real-world data

2024-5-23

Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

2024-5-21

Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia

2024-5-21

Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura

2024-5-20

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

2024-5-20

Disruption of the hippo pathway promotes the proliferation of childhood acute lymphoblastic leukemia cells, inhibits apoptosis and chemosensitivity

2024-5-20

Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?

2024-5-20

Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease

2024-5-16

Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma

2024-5-11